Printer Friendly

Research and Markets: Parasitic Helminths - Drug Discovery in Infectious Diseases.

DUBLIN -- Research and Markets ( has announced the addition of John Wiley and Sons Ltd's new book "Parasitic Helminths. Drug Discovery in Infectious Diseases" to their offering.

This third volume in the successful 'Drug Discovery in Infectious Diseases' series is the first to deal with drug discovery in helminthic infections in human and animals. The result is a broad overview of different drug target evaluation methods, including specific examples of successful drug development against helminthes, and with a whole section devoted to vaccine development.

With its well-balanced mix of high-profile contributors from academia and industry, this handbook and reference will appeal to a wide audience, including parasitologists, pharmaceutical industry, epidemiologists, and veterinary scientists.

Key Topics Covered:


* Ligand gated Ion channels as targets for anthelmintic drugs: past, current and future perspectives

* How relevant is caenorhabditis elegans as a model for the analysis of parasitic nematode biology?

* Integrating and mining helminth genomes to discover and prioritize novel therapeutic targets

* Recent progress in transcriptomics of key gastrointestinal nematodes of animals: fundamental research toward new intervention strategies

* Harnessing genomic technologies to explore the molecular biology of liver flukes - major implications for fundamental and applied research

* RNA Interference: A potential discovery tool for therapeutic targets of parasitic nematodes

* RNA Interference as a tool for drug discovery in parasitic flatworms


* Mechanism-based screening strategies for anthelmintic discovery

* Identification and profiling of nematicidal compounds in veterinary parasitology

* Quantitative high-content screening-based drug discovery against helmintic diseases

* Use of rodent models in the discovery of novel anthelmintics

* To kill a mocking worm: Strategies to improve Caenorhabditis elegans as a model system for use in anthelmintic discovery


* Anthelmintic drugs: Tools and shortcuts for the long road from discovery to product

* Antinematodal drugs, modes of action and resistance: And worms will not come to thee

* Drugs and targets to perturb the symbiosis of Wolbachia and filarial nematodes

* Promise of Bacillus thuringiensis crystal proteins as anthelmintics

* Monepantel: From discovery to mode of action

* The discovery, mode of action and commercialization of Derquantel

* Praziquantel: Too good to be replaced?

* Drug discovery for trematodiases: Challenges and progress


* Barefoot thru' the Valley of Darkness: Preclinical development of a human hookworm vaccine

* Vaccines linked to chemotherapy: A new approach to control helminth infections

* Antifilarial vaccine development: Present and future approaches

* Proteases as vaccines against gastrointestinal nematode parasites of sheep and cattl

* Schistosomiasis vaccines: New approaches to antigen discovery and promising new candidates

* Sm14 Schistosoma mansoni fatty acid-binding protein: Molecular basis for an antihelminth vaccine

* Mechanisms of immune modulation by Fasciola hepatica: Importance for vaccine development and for novel immunotherapeutics

* Prospects for immunoprophylaxis against Fasciola hepatica (liver fluke)

* Vaccines Against Cestode Parasites


* Conor R. Caffrey.

* Paul M. Selzer.

For more information visit

Source: John Wiley and Sons Ltd
COPYRIGHT 2012 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jul 24, 2012
Previous Article:SunGard to Announce Second Quarter Results on July 31, 2012.
Next Article:Tyler Technologies Signs $8 Million ERP Contract With the City of Charlotte, N.C.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters